No­var­tis vets get $35M to pluck one of the phar­ma gi­ant’s aban­doned drugs off the shelf and put it back in­to a clin­i­cal tri­al

Back in 2006, No­var­tis ex­ecs scooped up rights to Ky­orin’s im­muno­sup­pres­sant drug pro­gram for KRP-203, an S1P drug that the phar­ma gi­ant ini­tial­ly thought had some re­al po­ten­tial.

But Mayzent (sipon­i­mod) ul­ti­mate­ly stole the S1P show at No­var­tis, which would go on to win a first-in-class FDA OK in mul­ti­ple scle­ro­sis, with KRP-203 aban­doned along the way still in ear­ly-stage de­vel­op­ment.

Un­til to­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.